{"filing":{"accession_number":"0001193125-26-282988","cik":"0000818033","ticker":"HRTX","company_name":"HERON THERAPEUTICS, INC. /DE/","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"hrtx-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526282988/hrtx-20260625.htm"},"events":[{"id":13983,"run_id":12434,"accession_number":"0001193125-26-282988","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Heron Therapeutics received a written notice from Nasdaq on June 25, 2026, that its common shares failed to meet the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market. The company has been granted a 180-day compliance period (until December 22, 2026) to cure the deficiency, with potential for an additional 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access.","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11285,"accession_number":"0001193125-26-282988","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Heron Therapeutics received a written notice from Nasdaq on June 25, 2026, that its common shares failed to meet the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market. The company has been granted a 180-day compliance period (until December 22, 2026) to cure the deficiency, with potential for an additional 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:01:47.651105+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11285,"accession_number":"0001193125-26-282988","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Heron Therapeutics received a written notice from Nasdaq on June 25, 2026, that its common shares failed to meet the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market. The company has been granted a 180-day compliance period (until December 22, 2026) to cure the deficiency, with potential for an additional 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T21:01:47.651105+00:00","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-06-25"}]}